BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
October 17, 2024 08:07 ET
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
Ivy Brain Tumor Center to Present Multiple Abstracts and a Special Session on Innovative Clinical Trial Design at the 2024 European Association of Neuro-Oncology Annual Meeting
October 17, 2024 06:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute will present updated study results and a special session on clinical trial design at the...
Clinical Trial Patient Recruitment Services Market to Hit US$ 19.1 Billion by 2031 at 8.2% CAGR, Says CoherentMI
October 16, 2024 10:02 ET
|
CMI
Burlingame, Oct. 16, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Clinical Trial Patient Recruitment Services Market is estimated to value at US$ 9.4 Billion in the year 2024 and...
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
October 16, 2024 07:00 ET
|
OKYO Pharma LTD
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The...
$3.8 Million Department of Defense Grant Awarded for Groundbreaking Study on Safe and Sound Protocol in PTSD Treatment
October 10, 2024 10:00 ET
|
Unyte Health
The study aims to determine if filtered music as an adjunct therapy can reduce PTSD symptoms and enhance treatment for civilian and military populations.
International Myeloma Foundation Launches Clinical Trial Matching Engine in Partnership with SparkCures
October 10, 2024 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is excited to announce that it has partnered with SparkCures to bring an innovative solution to...
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
October 10, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
October 09, 2024 10:47 ET
|
Lipella Pharmaceuticals Inc.
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases...
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
October 09, 2024 08:00 ET
|
Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301
October 08, 2024 08:00 ET
|
ImmuneSensor Therapeutics
DALLAS, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists targeting...